Transgene Announces Rights Offering

Apr 23, 2001, 01:00 ET from Transgene

    STRASBOURG, France, April 23 /PRNewswire Interactive News Release/ --
 Transgene (Nasdaq:   TRGNY; Nouveau Marche: TRANSGENE) announced today
 information concerning a capital increase in the form of a rights offering for
 new shares.  Transgene is offering its new shares pursuant to statutory
 preferential rights under French law to existing holders of its shares and
 American Depositary Shares (one share equals three ADSs) in the ratio of
 11 share rights to purchase 10 new shares, or 33 ADS rights to purchase 30 new
 ADSs.  Transgene will offer a total of 5,314,990 new shares in the form of
 shares or ADSs at a subscription price of euro 15.00 per share (euro 5.00 per
 ADS).  The subscription period for the exercise of share rights will extend
 from April 27, 2001 to May 15, 2001 and the subscription period for the
 exercise of ADS rights will extend from April 27, 2001 to May 11, 2001.  The
 share rights will be listed on the Nouveau Marche of the Euronext Paris.
     The maximum amount of the capital increase will be euro 79,724,850.
     bioMErieux Pierre FABRE, which holds directly or indirectly 52.8% of
 Transgene's outstanding shares, has informed Transgene that it intends to
 exercise all share rights related to the shares it held prior to the rights
 offering at an aggregate subscription price of euro 42,066,810 and to
 subscribe for up to 1,181,789 additional shares, subject to reduction, at an
 additional aggregate subscription price of up to euro 17,726,835.
     Transgene has filed a Note d'Operation with the Commission des Operations
 de Bourse (COB) in France and has filed a Registration Statement with the
 Securities and Exchange Commission, which has not yet become effective.  These
 securities may not be sold nor may offers to buy be accepted prior to the time
 the registration statement becomes effective.  This press release shall not
 constitute an offer to sell or the solicitation of an offer to buy nor shall
 there be any sale of these securities in any State in which such offer,
 solicitation or sale would be unlawful prior to registration or qualification
 under the securities laws of any such State.  The offering documents will
 available upon request from the Company at its main office at 11, rue de
 Molsheim, 67000 Strasbourg, France.
     Transgene, based in Strasbourg, France, with an office near Boston,
 Massachusetts, is a biopharmaceutical company dedicated to the discovery and
 development of and gene therapy products for the treatment of acquired or
 inherited diseases for which there is no cure or adequate therapy at present.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X37070743
 
 

SOURCE Transgene
    STRASBOURG, France, April 23 /PRNewswire Interactive News Release/ --
 Transgene (Nasdaq:   TRGNY; Nouveau Marche: TRANSGENE) announced today
 information concerning a capital increase in the form of a rights offering for
 new shares.  Transgene is offering its new shares pursuant to statutory
 preferential rights under French law to existing holders of its shares and
 American Depositary Shares (one share equals three ADSs) in the ratio of
 11 share rights to purchase 10 new shares, or 33 ADS rights to purchase 30 new
 ADSs.  Transgene will offer a total of 5,314,990 new shares in the form of
 shares or ADSs at a subscription price of euro 15.00 per share (euro 5.00 per
 ADS).  The subscription period for the exercise of share rights will extend
 from April 27, 2001 to May 15, 2001 and the subscription period for the
 exercise of ADS rights will extend from April 27, 2001 to May 11, 2001.  The
 share rights will be listed on the Nouveau Marche of the Euronext Paris.
     The maximum amount of the capital increase will be euro 79,724,850.
     bioMErieux Pierre FABRE, which holds directly or indirectly 52.8% of
 Transgene's outstanding shares, has informed Transgene that it intends to
 exercise all share rights related to the shares it held prior to the rights
 offering at an aggregate subscription price of euro 42,066,810 and to
 subscribe for up to 1,181,789 additional shares, subject to reduction, at an
 additional aggregate subscription price of up to euro 17,726,835.
     Transgene has filed a Note d'Operation with the Commission des Operations
 de Bourse (COB) in France and has filed a Registration Statement with the
 Securities and Exchange Commission, which has not yet become effective.  These
 securities may not be sold nor may offers to buy be accepted prior to the time
 the registration statement becomes effective.  This press release shall not
 constitute an offer to sell or the solicitation of an offer to buy nor shall
 there be any sale of these securities in any State in which such offer,
 solicitation or sale would be unlawful prior to registration or qualification
 under the securities laws of any such State.  The offering documents will
 available upon request from the Company at its main office at 11, rue de
 Molsheim, 67000 Strasbourg, France.
     Transgene, based in Strasbourg, France, with an office near Boston,
 Massachusetts, is a biopharmaceutical company dedicated to the discovery and
 development of and gene therapy products for the treatment of acquired or
 inherited diseases for which there is no cure or adequate therapy at present.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X37070743
 
 SOURCE  Transgene